Close Menu

NEW YORK — AmoyDx said on Tuesday that it has partnered with Janssen Research and Development to develop a next-generation sequencing-based companion diagnostic for the Chinese market.

Under the terms of the deal, Xiamen, China-based AmoyDx will develop and secure Chinese regulatory approval for its LC10 Essential NGS panel as a companion diagnostic to an undisclosed cancer therapy.

Additional terms were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.